Atopic Dermatitis: Upadacitinib Effective in Two Phase 3 Trials ...Middle East

Medscape - News
The JAK inhibitor, currently approved for rheumatoid arthritis, yielded improvements in skin clearance, itch, and quality of life for nearly 1700 patients with moderate to severe disease. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Atopic Dermatitis: Upadacitinib Effective in Two Phase 3 Trials )

Apple Storegoogle play

Also on site :